Skip to main content
Premium Trial:

Request an Annual Quote

BioImage to Use RNAx s RNAi-Knockdown Tool in Its Assay Technology

NEW YORK, Jan. 27 (GenomeWeb News) - RNAx yesterday said it will provide BioImage with its RNAi-knockdown technology.

 

The agreement will "complement" BioImage's Redistribution assay technology, and "vice versa."

 

"The goal of the agreement is to provide both RNAx's and BioImage's customers with both technologies from one source, the companies said in s statement.

 

Financial details of the agreement were not disclosed.


BioImage's Redistribution technology enables high-throughput, high-content screening on many targets of "current interest" in drug discovery, including a "range" of intracellular signaling molecules and cell-surface receptors, the companies said.

 

RNAx's technology, meantime, provides for automated validation of siRNAs and targets, including those for which BioImage has developed assays.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.